Vetr Upgrades Merrimack Following Earnings, Licensing Rumors

Loading...
Loading...

The Vetr crowd upgraded their rating for Merrimack Pharmaceuticals Inc MACK from the previous rating of 2 stars (Sell), issued 20 days ago, to 5 stars (Strong Buy). Sentiment in the stock among the crowd is still middling, with 57 percent of Vetr user ratings bullish.

Interest in Merrimack jumped earlier this month upon rumors that the company was working with investment banks on the possibility of licensing its cancer treatment drug to larger biopharmaceutical companies. Shares of Merrimack traded recently around $6.03, about 10.7 percent lower from where it was at its post-rumor high of $6.75 on November 14.

See how crowdsourced ratings could help you time the markets.

The crowd's target price for Merrimack is at $10.86, which is just below the average analyst target price of $11.00. Less than 2 percent of Vetr users are holding MACK in their watch lists.

date
ticker
name
Price Target
Upside/Downside
Recommendation
Firm
Posted In: BiotechUpgradesRumorsCrowdsourcingAnalyst RatingsGeneralVetr
We simplify the market for smarter investing

Trade confidently with insights and alerts from analyst ratings, free reports and breaking news that affects the stocks you care about.

Join Now: Free!

Loading...